Another phenibut product shows up in warning letter

By Hank Schultz contact

- Last updated on GMT

©Getty Images - serggn
©Getty Images - serggn

Related tags: nootropics, Cognitive health, mood support, regulations

An FDA warning letter to the marketer of a product containing phenibut took the company to task over noncompliant disease claims but made no mention of the legal status of the ingredient itself.

FDA sent a warning letter to Chicago-based firm Synaptent, LLC on Nov. 9 and posted the letter on Dec. 7.  The letter includes a long list of allegedly non compliant disease claims on a number of products the company markets.  Those include products based on curcumin, fisetin, Lion’s mane mushroom, quercitin, Boswellia serrata​ and others.  As with other warning letters in the current climate, it came as a result of a review of the company’s website, not as a result of a physical inspection.

Anti-inflammatory claims most often cited violation

The claims listed in the warning letter including anti inflammatory, antibacterial and antimicrobial claims.  The warning letter also cited products aimed at hangover relief.

But front and center in the warning letter was a mention of several of Synaptent’s products based on phenibut. Phenibut is also known as aminophenylbutyric acid among many other synonyms.  It was reportedly was first developed in the Soviet Union in the 1960s.

Phenibut has a chemical structure similar to the brain chemical called gamma-aminobutyric acid (GABA).  The ingredient has been used to treat anxiety, insomnia, post traumatic stress disorder, alcoholism and other conditions.  It has reportedly also been used as a recreational drug.  It is openly for sale on Internet sites like Nootropics Depot and by companies like Synaptent.

Phenibut on notice since 2019

In 2019 the US Food and Drug Administration sent warning letters to three companies about the use of phenibut​.  At the time the Agency said,”Phenibut is a substance that does not meet the statutory definition of a dietary ingredient. . . Because phenibut does not fit any of the categories of dietary ingredients under the FD&C Act, any dietary supplements that declare phenibut as a dietary ingredient are misbranded.”

The warning letter to Syanptent notes that the company was making a number of allegedly noncompliant disease claims for its phenibut products including that they are “neuroprotective and anxiolytic”​ and are “said to support relaxation, restful sleep, and positive mood.”

The warning letter, however, made no specific mention of phenibut’s regulatory status.

Independent observers say they’ve found data that FDA’s enforcement actions on phenibut have had little effect in any case.  A study conducted by a team led by prominent industry critic Dr Pieter Cohen of Harvard Medical School and published early in the fall found that after the 2019 enforcement action not only did phenibut not disappear from the market, but that some marketers actually increased the dosages of their products​.

In response to a query from NutraIngredients-USA about the lack of reference to the ingredient's regulatory status FDA issued this statement: "The Agency’s stance on phenibut has not changed. The language you’re referring to applies when phenibut is marketed as a dietary ingredient or as a dietary supplement​."

Related news

Related products

show more

Plant-based Proteins Collection from Ingredients4U

Plant-based Proteins Collection from Ingredients4U

Ingredients4u AG | 03-May-2022 | Technical / White Paper

Plant-based products have always been a hot topic in the market, the plant-based food market was valued at $29.4 billion in 2020. Ingredients4U is one...

The Year of

The Year of "Destination Health" Has Arrived

Blue California | 01-Apr-2022 | Infographic

Consumers are pursuing prevention over cure as the ticket to long-term health and wellness. While immunity is at the forefront of health, consumers are...

Related suppliers

Follow us

Products

View more

Webinars